Skip to main content

Advertisement

SpringerLink
Log in

A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rothenberg M, Eckardt J, Kuhn J, Burris H, Nelson J, Hilsengeck S, Rodriguez G, Thurman A, Smith L, Eckardt S, Weiss G, Elfring G, Rinaldi D, Schaaf L, Von Hoff D: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14: 1128–1135, 1996

    CAS  PubMed  Google Scholar 

  2. de Forni M, Bugat R, Chabot G, Culine S, Extra J-M, Gouyette A, Madelaine I, Marty M, Mathieu-Boué A: Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54: 4347–4354, 1994

    CAS  PubMed  Google Scholar 

  3. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14: 2101–2112, 1996

    CAS  PubMed  Google Scholar 

  4. Millar JL, McElain TJ, Clutterbuck RD, Wist EA: The modification of melphalan toxicity in tumor bearing mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR2721). Am J Clin Oncol 5: 321–328, 1982

    CAS  PubMed  Google Scholar 

  5. Rougier P, Bugat R, Douillard JY, Culine S, Suc E Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15: 251–260, 1997

    CAS  PubMed  Google Scholar 

  6. Delioukina ML, Prager D, Parson M, Hecht JR, Rosen P, Rosen LS: Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma. Cancer 94: 2174–2179, 2002

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stanford Clinical Cancer Center, Stanford, CA, 94305-5826, USA

    Heather Wakelee MD & George A. Fisher

  2. 875 Blake Wilbur Drive, Room 2231, Stanford, CA, 94305-5826

    Heather Wakelee MD

Authors
  1. Heather Wakelee MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George A. Fisher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heather Wakelee MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wakelee, H., Fisher, G.A. A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer. Invest New Drugs 23, 241–242 (2005). https://doi.org/10.1007/s10637-005-6732-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-005-6732-1

Key words

Search

Navigation